Skip to main content
Caplight Logo









Regenyx Medical

Regenyx Medical

Private
IsraelHealthcare & Life Scienceshttps://regenyxmed.com/

Last Round

Accelerator

Jun 5, 2025

Total Funding Raised

$2.4M

Company Overview

Regenyx Medical is a biotechnology company that develops peptide-based hydrogel biomaterials for soft tissue restoration and bone healing applications.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Advanced Materials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicinebiomaterialspeptide hydrogelfat graftingsoft tissue fillerbone graftmedical deviceaesthetic medicinereconstructive surgerytissue engineeringbiotechscaffold technologyautologous fat transferinjectable fillers

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Regenyx Medical Comparables

Compare Regenyx Medical with similar companies based on industry and business-model similarity.

Regenyx Medical comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
inSoma Bio
83%
Conexeu Sciences Inc.
77%
BellaSeno
75%

Regenyx Medical Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorJun 5, 2025
GrantJul 1, 2023
GrantFeb 1, 2021

Key People

Founding team and executive leadership

Nadav Orr

Chief Technology Officer

Executive Team

Regenyx Medical Investors

Notable investors and investment history

Regenyx Medical investors
InvestorRounds
MedTech InnovatorAccelerator
Israel Innovation AuthorityGrant
American Society of Plastic SurgeonsAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 5, 2025

    Received funding from MedTech Innovator and ASPS.

  • Jul 2, 2024

    Grew 150% QoQ, from 2 to 5 employees.

Regenyx Medical Filings

Explore SEC and related filing metadata, where available.

Regenyx Medical filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Regenyx Medical's valuation, stock price, and market status.

Is Regenyx Medical a public or private company?

Regenyx Medical is a private company.

What is the current stock price of Regenyx Medical?

Regenyx Medical is a private company with no public stock price. Caplight tracks Regenyx Medical's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Regenyx Medical worth (valuation)?

Valuation information for Regenyx Medical is not publicly available.

Can I buy Regenyx Medical stock?

Regenyx Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Regenyx Medical's last funding round?

Regenyx Medical's most recent funding round was Accelerator on June 5, 2025.

Who are the main investors in Regenyx Medical?

Key investors in Regenyx Medical include Israel Innovation Authority.

Will Regenyx Medical IPO soon?

No public IPO plans have been announced for Regenyx Medical.

How can I track Regenyx Medical secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Regenyx Medical's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIsrael
Employee Range2
Year Founded2016
Last FundingJun 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?